CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Relmada Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Relmada Therapeutics Inc
2222 Ponce De Leon Blvd. 3Rd Floor
Phone: (646) 876-3459p:646 876-3459 CORAL GABLES, FL  33134  United States Ticker: RLMDRLMD

Business Summary
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Charles J.Casamento 77 6/15/2017 7/14/2015
Chief Executive Officer, Director Sergio C.Traversa 62 7/29/2019 4/1/2012
Chief Financial Officer Maged S.Shenouda 58 1/9/2020 11/12/2015
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Relmada Therapeutics, Inc.
RLMD
RLMDD

General Information
Number of Employees: 20 (As of 12/31/2023)
Outstanding Shares: 30,174,202 (As of 3/15/2024)
Shareholders: 129
Stock Exchange: NASD
Federal Tax Id: 455401931


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024